



**DIRECTING
IMMUNITY
DIRECTLY**

APRIL 2020

Forward-looking statements

The information contained in this presentation is provided by Vaxil Bio Ltd. (“Vaxil”) for informational purposes only and does not constitute an offer to issue or arrange to issue, or the solicitation of an offer to issue, securities of VAXIL or other financial products. The information contained herein is not investment or financial product advice and is not intended to be used as the basis for making an investment decision. The views, opinions and advice provided in this presentation reflect those of the individual presenters, and are provided for information purposes only. The presentation has been prepared without taking into account the investment objectives, financial situation or particular needs of any particular person. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of VAXIL nor its directors, officers, employees or agents, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of the information contained in this presentation. Except for statements of historical fact, this presentation contains certain “forward-looking information” within the meaning of applicable securities laws. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements, including, among others, VAXIL’s future growth and development, the proposed plans of any of VAXIL’s equity holdings, as well as those risk factors identified in VAXIL’s Filing Statement and other disclosure documents available at www.sedar.com under VAXIL’s name. VAXIL undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. This presentation does not constitute an offer of shares for sale in the United States or to any person that is, or is acting for the account or benefit of, any U.S. person (as defined in Regulation S under the United States Securities Act of 1933, as amended (the “Securities Act”) (“U.S. Person”), or in any other jurisdiction in which such an offer would be illegal. VAXIL’s shares have not been and will not be registered under the Securities Act.

COVID-19 Experiment #1 Abstract


Aim: Establish signal peptide candidate immunogenicity by assessing T cell proliferation

Method: Healthy donor peripheral blood mononuclear cells (PBMCs) stimulated by peptide-loaded autologous dendritic cells


Results: T cell (CD3⁺) proliferation was observed by flow cytometry for all candidate signal peptides, to varying degrees, compared to unstimulated cells.
Proliferation was also observed in T cell subpopulations – cytotoxic T lymphocytes (CD8⁺) and, more pronouncedly, helper T cells (CD4⁺).

Experiment Results - Population Gating


Lymphocyte gating




T cell gating




Cytotoxic T lymphocyte and helper T cell gating




Experiment Results - T Cell (CD3⁺) Proliferation




Experiment Results - Helper T Cell (CD4⁺) Proliferation



Experiment Results - Cytotoxic T Lymphocyte (CD8⁺) Proliferation



ImMucin Stimulation Index



Adapted from Kovjazin et al., Vaccine, 2011